Freenome, Inc. (FRNM)
The price, the headline numbers and the latest news, in one place.
Freenome, Inc. (FRNM) Stock Price, Analysis & Data
| Bid | 16.71 |
| Market Cap | 1.69B |
| Revenue (ttm) | 35.4M |
| Net Income (ttm) | -235M |
| 0.48 | |
| -2.07 | |
| n/a | |
| -6.56 | |
| P/B (ttm) | -0.30 |
| P/S (ttm) | 47.79 |
| Earnings Date | n/a |
| Ask | 14.97 |
| Volume | 401,072 |
| Avg. Volume (20D) | 594,898 |
| Open | 15.96 |
| Previous Close | 15.99 |
| Day's Range | 15.52 - 16.10 |
| 52-Week Range | 9.95 - 17.18 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About FRNM
Freenome, Inc. operates as a biotechnology company in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops blood-based tests, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, panc...
Financial Performance
In 2025, Freenome's revenue was 30.41M, an increase of 955.14% compared to the previous year's 2.88M. Earnings were -219.34M, a decrease of -20.07%.
Financial StatementsEarnings Surprise
- Revenue of n/a misses estimates by $0, with NaN% YoY growth.
- EPS of misses estimates by , with NaN% YoY growth.
1 month ago · Investor's Business Daily
Guardant Health, Thursday's Stock Of The Day, Spikes After Hiking 2026 OutlookGuardant Health is Thursday's IBD Stock Of The Day in a thriving market for colon cancer screening tests. On Friday, Guardant Health stock surged after the company raised full-year outlook after a Q2...